BioSpace News Archive

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) securities between September 16, 2019 and June 29, 2020, inclusive (the “Class Period”).

Cognate BioServices, Inc. announced today the appointments of Timothy Moore and Steven Kasok as independent non-executive members of its Board of Directors. “We are excited to welcome Tim Moore and

Karmanos Specialty Pharmacy is pleased to announce that it has received full accreditation from the Utilization Review Accreditation Commission.

Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a Type C meeting with the FDA Office of Oncologic Diseases on August 11, 2020 to discuss miRagen’s future clinical development plans for cobomarsen for the potential treatment of Adult T-Cell Leukemia/Lymphom

Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021 Completed construction of cGMP clinical manufacturing facility Completed initial public offering of common stock on July 14, 2020, raising $289.8 million in gross proceeds Cash and cash equivalents of $341.8 million (pro forma) as of June 30, 2020, believed to be sufficient to fund operations into at least the second half of 2023 SOUTH SAN FRANCISCO, Calif

The combination of SmartPharm’s Gene Mab™ gene-encoded in vivo expression system and Sorrento’s SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. Beyond COVID-19, the synergies between Sorrento’s proprietary fully human G-MAB ™ Antibody Library and SmartPharm’s Gene-Encoded Therapeutics (GET) Platform are expected to provide a vast product pipeline of novel, long-acting therapeutic proteins for a broad range of diseases,

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced that its Board of Directors has promoted John P. Shannon to the position of President and Chief Operating Officer, effective immediately. In his new role, Mr. Shannon will be responsible for

TechnoVax, Inc, a biotechnology developer of novel vaccines and The CUNY School of Medicine at The City College of New York, announce a breakthrough in their collaborative effort to develop a vaccine for COVID-19.

Technology expansion provides AbCellera with the ability to combine any two antibodies generated through its discovery platform to create full IgG bispecifics Computational protein engineering expert Dr. Tim Jacobs joins AbCellera from Dualogics VANCOUVER, British Columbia--( BUSINESS WIRE )-- AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated pla